Drug Puts A $750,000 ‘Price Tag On Life’

KHN Original

The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.

Podcast: ‘What The Health?’ Now What?

KHN Original

In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Sarah Kliff of Vox.com, and Mary Agnes Carey of Kaiser Health News discuss what happens now in the wake of the apparent demise of the Republican-only repeal and replace efforts for the Affordable Care Act.

Podcast: What The Health? What A Week!

KHN Original

In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Sarah Kliff of Vox.com, and Mary Agnes Carey of Kaiser Health News deconstruct the drama leading to the middle-of-the-night collapse of Senate Republicans’ last-ditch effort to overhaul the Affordable Care Act.